IFRX Long Put Strategy
IFRX (InflaRx N.V.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
InflaRx N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and developing novel inhibitors leveraging C5a technology, primarily operating in Germany and the United States. The company's focus on C5a stems from its critical role as an inflammatory mediator implicated in the progression of various autoimmune and inflammatory diseases. Its primary product candidate, vilobelimab, is an innovative, first-in-class anti-C5a monoclonal antibody delivered intravenously. Vilobelimab has progressed through several clinical stages for multiple indications: It has successfully completed a Phase III clinical trial for hidradenitis suppurativa (HS), a rare, chronic, and debilitating systemic inflammatory skin condition. It is currently undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis (AAV), a rare and life-threatening autoimmune disorder, and for PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC). An exploratory Phase IIa study is also underway for pyoderma gangraenosum (PG), a chronic inflammatory skin disorder.
IFRX (InflaRx N.V.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $138.7M, a beta of 2.44 versus the broader market, a 52-week range of 0.741-2.949, average daily share volume of 1.8M, a public-listing history dating back to 2017, approximately 74 full-time employees. These structural characteristics shape how IFRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.44 indicates IFRX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a long put on IFRX?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current IFRX snapshot
As of June 30, 2026, spot at $2.25, ATM IV 366.50%, IV rank 72.71%, expected move 105.07%. The long put on IFRX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long put structure on IFRX specifically: IFRX IV at 366.50% is rich versus its 1-year range, which makes a premium-buying IFRX long put relatively expensive in absolute-cost terms, with a market-implied 1-standard-deviation move of approximately 105.07% (roughly $2.36 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IFRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on IFRX should anchor to the underlying notional of $2.25 per share and to the trader's directional view on IFRX stock.
IFRX long put setup
The IFRX long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IFRX near $2.25, the first option leg uses a $2.25 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IFRX chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IFRX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $2.25 | N/A |
IFRX long put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
IFRX long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on IFRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long put on IFRX
Long puts on IFRX hedge an existing long IFRX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying IFRX exposure being hedged.
IFRX thesis for this long put
The market-implied 1-standard-deviation range for IFRX extends from approximately $-0.11 on the downside to $4.61 on the upside. A IFRX long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long IFRX position with one put per 100 shares held. Current IFRX IV rank near 72.71% sits in the upper third of its 1-year distribution, which historically reverts; this raises the bar for premium-buying structures and lowers it for premium-selling structures on IFRX at 366.50%. As a Healthcare name, IFRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IFRX-specific events.
IFRX long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IFRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IFRX alongside the broader basket even when IFRX-specific fundamentals are unchanged. Long-premium structures like a long put on IFRX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current IFRX chain quotes before placing a trade.
Frequently asked questions
- What is a long put on IFRX?
- A long put on IFRX is the long put strategy applied to IFRX (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With IFRX stock trading near $2.25, the strikes shown on this page are snapped to the nearest listed IFRX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are IFRX long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the IFRX long put priced from the end-of-day chain at a 30-day expiry (ATM IV 366.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IFRX long put?
- The breakeven for the IFRX long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IFRX market-implied 1-standard-deviation expected move is approximately 105.07%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on IFRX?
- Long puts on IFRX hedge an existing long IFRX stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying IFRX exposure being hedged.
- How does current IFRX implied volatility affect this long put?
- IFRX ATM IV is at 366.50% with IV rank near 72.71%, which is elevated relative to its 1-year range. Premium-selling structures (covered call, cash-secured put, iron condor) generally look more attractive when IV rank is high; premium-buying structures (long call, long put, debit spreads) are more expensive in that regime.